DE4CC0DE-5FC3-4494-BCBF-4D50B00366B5

Johnson & Johnson Profit Tops Estimates as Drug Sales Rise

By Steve Wynne-Jones
Share this article
Johnson & Johnson Profit Tops Estimates as Drug Sales Rise

Johnson & Johnson reported quarterly earnings that topped analysts’ estimates as new cancer and diabetes treatments helped push drug sales higher.

First-quarter earnings, excluding one-time items, were $1.56 a share, compared with the $1.53 average estimate of analysts compiled by Bloomberg.

Pharmaceutical sales climbed 3 percent to $7.7 billion. The results underscore the company’s push to replenish its product lineup as drugs such as hepatitis C treatment Olysio and blood thinner Xarelto face new competition.

An additional challenge comes from the strong dollar, since J&J gets about half its sales outside the U.S. The company cut its forecast for full-year earnings to a range of $6.04 to $6.19 a share, down from a prior prediction of $6.12 to $6.27, because of the currency fluctuations. Analysts had predicted $6.17 on average, according to data compiled by Bloomberg.

“If you look operationally -- let’s take out foreign exchange -- the numbers are actually fairly strong,” said Tony Butler, an analyst at Guggenheim Securities LLC. “They’re still growing the pharma business, principally in immunology and oncology.”

ADVERTISEMENT

J&J probably won’t be alone in warning that the stronger dollar will continue to hurt earnings this year. Last quarter, the health-care company was the first of many drugmakers to report lower-than-expected guidance or sales declines due to the U.S. currency’s gain.

J&J’s consumer unit, which makes over-the-counter products like Tylenol and Motrin, fell 4.7 percent to $3.4 billion. Revenue for the medical-device business, which has been under pressure from cost-cutting by insurers and hospitals, dropped 11.4 percent to $6.3 billion.

Bloomberg News, edited by ESM

Get the week's top grocery retail news

The most important stories from European grocery retail direct to your inbox every Thursday

Processing your request...

Thanks! please check your email to confirm your subscription.

By signing up you are agreeing to our terms & conditions and privacy policy. You can unsubscribe at any time.